What Akkermansia Actually Is — and Why the Dead Version Worked Better
THE SHORT ANSWER
Akkermansia muciniphila is a bacterium that lives in your gut mucus layer and eats mucin. It makes up roughly 1–5% of gut bacteria, and lower levels track with obesity and type 2 diabetes. The finding that makes it unusual: in human trials the pasteurised form outperformed the live one. Heat-killed beat alive. That breaks the central assumption of the entire probiotic category, and it is why "live cultures" is the wrong thing to look for here. We do not sell it. This is what the evidence actually says.*
01What it is
Most gut bacteria live in the lumen — the open channel — and feed on what you eat. Akkermansia does something different. It lives inside the mucus layer coating your intestinal wall and uses mucin, the protein that mucus is made of, as its source of carbon and nitrogen.
That sounds destructive and is not. By grazing the mucus layer it appears to stimulate its renewal, and a thicker mucus layer means a better-maintained barrier between gut contents and bloodstream. It accounts for something like one to five percent of your gut bacteria.1
The interest started with a consistent observation: people with obesity, type 2 diabetes and hypertension tend to have less of it.2 That is correlation. What followed was an attempt to test causation in humans.
02The 2019 trial, and the result nobody expected
Forty overweight, insulin-resistant adults were randomised to live A. muciniphila, pasteurised A. muciniphila, or placebo for three months. Thirty-two completed.2
Both forms were safe and well tolerated. Then the surprise. Compared with placebo, the pasteurised form improved insulin sensitivity by 28.6% (p=0.002), reduced insulinaemia by 34.1% (p=0.006) and lowered total cholesterol by 8.7% (p=0.02).2
The live bacteria produced only borderline, mostly non-significant changes.
Heat-killing the organism made it work better. In a category built almost entirely on the premise that live cultures are the active ingredient, that is a genuinely strange result. The working explanation is that a specific protein on the bacterial membrane — which survives pasteurisation — does much of the signalling, rather than the living organism colonising anything.
One thing that gets overstated: weight change in that trial was not statistically significant. Body weight fell 2.27 kg but at p=0.091, and fat mass and hip circumference behaved the same way.2 Pages selling this as a weight-loss bacterium on the strength of the 2019 study are citing a result that did not reach significance.
03The 2026 trial — and what it actually measured
A larger randomised controlled trial followed, and the distinction in its design matters.
Ninety adults with overweight or obesity first did an eight-week low-energy diet to lose at least 8% of body weight. Then they were randomised to pasteurised A. muciniphila MucT or placebo for 24 weeks of normal eating.3
The supplemented group regained 1.2 kg against 3.2 kg for placebo (p=0.012), and ended with greater net loss from baseline (p=0.009).3
Read that carefully. It did not cause weight loss. The diet caused the weight loss. What it appeared to do was reduce regain afterwards — which is arguably a harder and more useful problem, but it is a different claim, and it only applies to someone who has already lost weight.
04Three things that should temper the enthusiasm
It works best in people who have least. Response tracked with baseline Akkermansia abundance in more than one study — the benefit concentrated in those starting low.3,4 Same pattern as iron, vitamin D and magnesium: repletion helps the depleted. If yours is already normal, expect less.
The company that sells it is in the research. The Akkermansia Company appears in the author affiliations on the 2026 trial.3 That does not make the result wrong — industry funds most nutrition research — but you should know, and most pages covering this will not tell you.
The evidence base is still small. Forty people in the pilot, ninety in the maintenance trial, 142 in a metabolic syndrome study.5 These are meaningful studies, not a settled literature. Reviews consistently call for larger and longer trials on dosing, formulation and durability.1
05Why we do not sell it
Two honest reasons.
It is an anaerobe and genuinely difficult to manufacture. The form with the human evidence is a specific pasteurised strain, and that is licensed rather than freely available — which means a bottle labelled simply "Akkermansia" may not contain the organism the trials used.
And we have committed publicly that if we make a probiotic it will be designated to strain level and verified to strain level on every lot. Species-level identity is not enough for an organism where a specific strain and a specific processing method carry the entire evidence base. We wrote about why in why we don't make a probiotic.
If we can meet that standard, we will make it. Until then we would rather write this page than sell you a capsule.
06What to check if you buy one elsewhere
- Strain, not species. The label should name the strain designation — MucT or the equivalent — not just "Akkermansia muciniphila".
- Pasteurised or live? The human evidence is on the pasteurised form. If a label leans on "live cultures" here, it is selling the opposite of what the trials support.
- Dose. Trials used around 1010 cells daily.
- A certificate you can actually see, verifying identity for the lot in your bottle rather than a typical batch. That applies to everything, not just this — how to read a certificate of analysis.
07What raises it without a supplement
Dietary fibre and polyphenols are the levers with the most support — the same unglamorous answer as most of gut health. If you want the distinction that decides which fibre, it is in soluble or insoluble.
08Frequently asked questions
What does Akkermansia muciniphila do?
It lives in the gut mucus layer and feeds on mucin, which appears to support renewal of that layer and the integrity of the gut barrier. Lower levels are associated with obesity and type 2 diabetes.1,2
Is pasteurised better than live?
In the human trials, yes. Pasteurised improved insulin sensitivity significantly where live did not.2 That is unusual for a probiotic and worth knowing before you shop.
Does Akkermansia cause weight loss?
The 2019 trial's weight change was not statistically significant.2 The 2026 trial showed reduced regain after a diet, not weight loss itself.3
Who is most likely to respond?
People with low baseline levels. Response tracked with starting abundance.3,4
Is it safe?
Both forms were safe and well tolerated in the trials, with no serious treatment-related adverse events.2,3 The trials are still relatively small.
Do you sell it?
No. We cannot yet guarantee strain-level verification on every lot, and we said we would not sell a probiotic without it.
09References
- Cani PD, Depommier C, Derrien M, Everard A, de Vos WM. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nat Rev Gastroenterol Hepatol. 2022;19(10):625–637. doi:10.1038/s41575-022-00631-9
- Depommier C, Everard A, Druart C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019. PMID: 31263284.
- Pasteurized Akkermansia muciniphila MucT for weight loss maintenance in people with overweight and obesity: a controlled randomized trial. Nat Med. 2026. PMID: 42120725. — author affiliations include The Akkermansia Company SA.
- Akkermansia muciniphila supplementation in patients with overweight/obese type 2 diabetes: efficacy depends on its baseline levels in the gut. Cell Metab. 2025.
- Effect of pasteurized Akkermansia muciniphila MucT on insulin sensitivity, body composition, and GLP-1 production in subjects with metabolic syndrome. PMID: 42343233.
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
